Scribe Therapeutics starts Phase 1 trial of PCSK9 silencer STX-1150, completes upsized IPO
Cardiovascular gene-editing company reports first clinical data expected in H1 2027 and cash runway into H1 2029 after $155.5 million IPO and Sanofi private placement.
Scribe Therapeutics reported second quarter 2026 results on September 2, 2026, highlighted by the start of its first clinical program. The company initiated a first-in-human Phase 1 clinical trial in Australia for STX-1150, its epigenetic silencing therapy that uses the ELXR technology to repress PCSK9 for LDL-C lowering, with the study evaluating safety, tolerability, and efficacy in adults with elevated LDL-C and increased ASCVD risk.1 Scribe said it anticipates reporting initial data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose portion of the trial in the first half of 2027.1
Supporting the program, the company presented late-breaking data at the European Atherosclerosis Society Congress showing that in non-human primates, a single dose of an STX-1150 prototype produced PCSK9 silencing of up to 90% and LDL-C reductions of up to 68%, with a 0.75 mg/kg dose sustaining LDL-C reductions greater than 50% for two years.1
On the earlier-stage pipeline, Scribe was awarded approximately $25.7 million in combined CIRM grants, including $12.7 million for STX-1200 and $13.0 million for STX-1400, both aimed at clinical entry as early as 2027.1 STX-1200 surrogates achieved greater than 95% Lp(a) reduction in NHP preclinical studies,1 while STX-1400 surrogates achieved greater than 75% on-target APOC3 editing in NHPs.1
On financing, Scribe's common stock began trading on Nasdaq under "SCTX" on July 24, 2026, after an upsized IPO priced at $15.00 per share along with a concurrent private placement to Sanofi.1 The IPO, full underwriter option exercise, and private placement together raised approximately $155.5 million in gross proceeds.1 Cash, cash equivalents, and marketable securities stood at $43.0 million as of June 30, 2026, down from $58.0 million at year-end 2025.1 Combined with IPO and placement proceeds, the company said this funding is expected to support operations into the first half of 2029.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.